Should You Buy, Hold or Sell ACB Stock Post Q3 Earnings Release?

Aurora Cannabis beat Q3 earnings and sales estimates as medical cannabis momentum drove growth, but persistent consumer weakness pressured the stock outlook.

Zacks Investment Research • Feb 6, 2026

Aurora Cannabis Reports Increased Revenue And Free Cash Flow For Q3-2026

Aurora Cannabis Inc. reported in-line financial results for Q3-2026 with increasing revenue and free cash flow. The company will divest its plant propagation segment and focus on international growth with higher profit margins. The company reported lower revenue for consumer cannabis as it prioritizes its cannabis sales for medical and international markets.

Seeking Alpha • Feb 5, 2026

Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript

Aurora Cannabis Inc. (ACB:CA) Q3 2026 Earnings Call Transcript

Seeking Alpha • Feb 4, 2026

Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program

NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has filed a prospectus supplement establishing a new at-the-market offering program (the "ATM Program") that allows the Company to issue and sell up to U.S.$100 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at the Company's discretion. The Company intends to use the net proceeds from the Offering for strategic and accretive purposes only, including for increased cultivation capacity and M&A.

PRNewsWire • Feb 4, 2026

Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue 1 Increasing by 12% to a Record $76.2 million Delivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income 1 of $7.2 million Generates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2 EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025. "Aurora has established a commanding leadership position within the rapidly expanding, high margin, global medical cannabis market.

PRNewsWire • Feb 4, 2026

Aurora Launches New European Websites, Showcasing Science-Backed Cannabis Leadership

NASDAQ | TSX: ACB Launch of improved, localized websites underscores Aurora's long-term strategy for growth and engagement across key European medical markets EDMONTON, AB, Feb. 3, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the launch of four brand new websites to support key European markets, continuing its investment in the region through a more focused, locally-relevant digital presence. The refreshed platforms are designed to better reflect Aurora's science-backed approach, manufacturing expertise, and brand strength, while improving engagement with healthcare professionals, partners, and prospective employees across Europe.

PRNewsWire • Feb 3, 2026

Aurora Secures EU Community Plant Variety Rights for Two Proprietary Cannabis Varieties

NASDAQ | TSX: ACB European grant advances Aurora's unparalleled leadership in cannabis genetics, enhancing its position as a leading medical cannabis company EDMONTON, AB, Jan. 20, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, today announces that it has been granted community plant variety rights by the EU's Community Plant Variety Office for two of its proprietary cannabis varieties. This achievement further strengthens the company's intellectual property portfolio and reinforces its commitment to innovation and cannabis genetics excellence.

PRNewsWire • Jan 20, 2026

How to play cannabis stocks in 2026

President Trump's executive order to reschedule marijuana is one of the many things cannabis investors will be watching in 2026. AdvisorShares portfolio manager Dan Ahrens, who manages the firm's Pure US Cannabis ETF, joins Asking for a Trend to explain where the cannabis industry stands right now.

Yahoo Finance • Jan 18, 2026

Aurora Achieves Significant Progress in Disease Resistance Research

NASDAQ | TSX: ACB As a leading global medical cannabis company, advancements in breeding, testing and production trials for powdery mildew-resistant cultivars reinforce Aurora's leadership in cannabis science EDMONTON, AB, Jan. 14, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce significant progress in its powdery mildew (PM) resistance research, nearly one year after the company's breakthrough discovery of a novel source of genetic resistance against powdery mildew, PM2. Since the initial discovery, Aurora has performed multiple rounds of crosses to transfer PM2 resistance into elite breeding lines.

PRNewsWire • Jan 14, 2026

3 Marijuana Stocks For Investors To Make Money In 2026

Finding the best marijuana stocks in the stock market today may be easier than you think. At one time, it was a simple task to determine which cannabis companies were better to invest in. Even with the sector's many ups and downs and constant issues with momentum, the sector is still on the rise. In 2026, there is much to look forward to that could not only push the industry forward but also turn a profit for shareholders.